Why the Immuron (ASX:IMC) share price fell today

The Immuron (ASX:IMC) share price closed lower today following the company’s recently released earnings report. Here’s the run down.
The post Why the Immuron (ASX:IMC) share price fell today appeared first on The Motley Fool Australia. –

woman in lab coat conducting testing representing mesoblast share price

The Immuron Ltd (ASX: IMC) share price closed over 4.4% lower today at 22 cents a share.

The slide follows the release of the biotechnology company’s half-year (1H21) results for the period ended 31 December 2020.

Let’s take a closer look at how Immuron has been performing recently.

What did Immuron report?

The company reported a 98.7% revenue crash for the period, with 1H21 revenue coming in at $20,000.

Immuron incurred a $5.7 million loss for the period, which was 277.2% greater than the $1.5 million loss of 1H20.

Compared to 30 June 2020, the group’s net assets increased from $5.6 million to $28.5 million as of 31 December 2020. Cash reserves also increased over this period from $3.3 million to $26.4 million.

The business received $358,280 during the period via the government’s research and development (R&D) income tax concession program.

The Immuron share price lost 2.6 cents a share for the 1H21 period, versus a loss of 9 cents a share for 1H20.

Clinical progress and updates

Immuron’s focus is the development and sale of oral immunotherapeutics to prevent and treat unmet medical needs. The company’s orally active polyclonal antibodies provide a targeted delivery inside the gastrointestinal tract so they do not cross into the bloodstream

The company advised that it continued to progress a number of clinical developments during the 1H21 period. 

Some milestones reached include receiving written guidance from the US Food and Drug Administration (FDA) in relation to a new drug the company is developing, completing a successful vaccination campaign, and executing a research agreement with Monash University.

Immuron also recommenced its Travelan US registration strategy. Travelan is an over-the-counter supplement that can be taken to reduce the risk of travellers’ diarrhoea. The company notes that the coronavirus has significantly disrupted international travel throughout the world. According to Immuron, COVID continues to impact every Travelan market.

Immuron share price snapshot

The Immuron share price has gained 60.7% over the previous year, however, it’s fallen 29.7% over the past 6 month period.

The company’s market capitalisation is approximately $51.1 million and there are 227.2 million shares outstanding.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Immuron (ASX:IMC) share price fell today appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!